文献速递白血病

慢性期CML患者停用TKI后停药综合征与心理问题的发生率及相关因素

[Incidence and associated factors of tyrosine kinase inhibitor withdrawal syndrome and psychological issues in patients with chronic-phase chronic myeloid leukemia after therapy discontinuation].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

该回顾性研究纳入158例在北京大学人民医院停用TKI的CML-CP患者,中位随访25个月,4年持续MMR率为60%。32%患者发生TKI停药综合征,32%报告焦虑等心理问题;停药时年龄大、TKI治疗时间长和DMR持续时间长与停药综合征相关,大学及以上学历和因妊娠或不良反应停药与心理问题相关。

要点

  • CML-CP患者停用TKI后停药综合征和焦虑等心理问题各约32%。
  • 停药时年龄大、TKI治疗时间长、DMR持续时间长增加停药综合征风险。
  • 大学及以上学历、因妊娠或不良反应停药与心理问题相关。

核心结论

  • 停用TKI的CML-CP患者中停药综合征和心理问题较为常见。
  • 停药综合征和心理问题的发生与停药后MMR丧失率无关。

研究设计与样本

  • 回顾性分析北京大学人民医院2012年9月以后停用TKI的CML-CP患者临床资料。
  • 共纳入158例患者,女性92例(58%),中位停药年龄50(IQR 35~60)岁。
  • 采用Logistic回归模型探讨停药综合征和心理问题发生的独立影响因素。

主要发现

  • 停药后中位随访25(IQR 11~49)个月,停药4年MMR未丧失生存率为60%(95% CI:51%~70%)。
  • 51例(32%)患者在停用TKI中位1.3(IQR 0.5~2.0)个月时发生停药综合征。
  • 51例(32%)患者报告焦虑等心理问题,源于担心BCR::ABL1水平波动或疾病复发,或因妊娠停药担心胎儿不良影响和遗传CML。
  • 停药时年龄大(纳入TKI治疗时间时P=0.003;纳入DMR持续时间时P=0.002)、TKI治疗时间长(P=0.010)和DMR持续时间长(P=0.005)与停药综合征风险升高显著相关。
  • 大学及以上学历(P=0.010)和因妊娠或药物不良反应停用TKI(P=0.001)与停药后心理问题显著相关。

临床怎么用

  • 对停用TKI的CML-CP患者应关注停药综合征和焦虑等心理问题。
  • 停药时年龄较大、TKI治疗时间长或DMR持续时间长的患者需警惕停药综合征。
  • 高学历及因妊娠或不良反应停药的患者应关注心理问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objectives: To investigate the incidence of tyrosine kinase inhibitor (TKI) withdrawal syndrome and psychological issues, and their associated factors, in patients with chronic-phase chronic myeloid leukemia (CML-CP) after TKI discontinuation. Methods: We retrospectively analyzed the clinical data of CML-CP patients who discontinued TKI therapy at Peking University People's Hospital after September 2012. Logistic regression models were used to identify independent factors associated with the occurrence of TKI withdrawal syndrome and psychological issues. Results: A total of 158 patients were included, of whom 92 (58%) were female. The median age at discontinuation was 50 (IQR, 35-60) years. With a median follow-up of 25 (IQR, 11-49) months, the 4-year rate of sustained major molecular response (MMR) was 60% (95% CI: 51%-70%) . Fifty-one (32%) patients experienced TKI withdrawal syndrome at a median of 1.3 (IQR, 0.5-2.0) months after TKI discontinuation. Fifty-one (32%) patients reported psychological issues such as anxiety. These concerns stemmed from fears of fluctuating BCR::ABL1 levels or disease relapse, and, for those who discontinued TKI for pregnancy, worries about adverse fetal effects and/or the fetus inheriting CML. Multivariable analyses revealed that older age at discontinuation [P=0.003 when adjusting for TKI therapy duration; P=0.002 when adjusting for deep molecular response (DMR) duration], longer TKI therapy duration (P=0.010) , and longer DMR duration before discontinuation (P=0.005) were significantly associated with a higher risk of TKI withdrawal syndrome; a university degree or higher (P=0.010) and TKI discontinuation due to pregnancy or adverse events (P=0.001) were significantly associated with psychological issues after discontinuation. The occurrence of TKI withdrawal syndrome or psychological issues had no impact on the probability of major molecular response loss after discontinuation. Conclusion: TKI withdrawal syndrome and psychological issues are common in CML patients who discontinue TKI therapy. Older age at discontinuation and longer TKI therapy duration or DMR duration are significantly associated with TKI withdrawal syndrome. Higher education level and TKI discontinuation due to pregnancy or adverse events are significantly associated with psychological issues. 目的: 探讨慢性髓性白血病慢性期(CML-CP)患者停用酪氨酸激酶抑制剂(TKI)后停药综合征和心理问题的发生及其影响因素。 方法: 回顾性分析北京大学人民医院2012年9月以后停用TKI的CML-CP患者停药前后的临床资料。应用Logistic回归模型探讨停药综合征和心理问题发生的独立影响因素。 结果: 共纳入158例患者,女性92例(58%),中位停药年龄50(IQR 35~60)岁。停药后中位随访25(IQR 11~49)个月,停药4年主要分子学反应(MMR)未丧失生存率为60%(95% CI:51%~70%)。51例(32%)患者在停用TKI中位1.3(IQR 0.5~2.0)个月时发生停药综合征。51例患者报告在停用TKI后因担心BCR::ABL1基因水平波动或疾病复发、TKI对胎儿的不良影响和(或)胎儿遗传CML而出现焦虑等心理问题。多因素分析显示,停药时年龄大[纳入TKI治疗时间时,P=0.003;纳入深层分子学反应(DMR)持续时间时,P=0.002]、TKI治疗时间长(P=0.010)和DMR持续时间长(P=0.005)是停用TKI后停药综合征发生的不利因素;受教育程度大学及以上(P=0.010)和因妊娠或药物不良反应停用TKI治疗(P=0.001)与停药后发生心理问题显著相关。停药综合征和心理问题的发生与停药后MMR丧失率无关。 结论: 在停用TKI的CML患者中,停药综合征和心理问题较为常见。停药时年龄大、TKI治疗时间长和DMR持续时间长与停药综合征的发生显著相关;受教育水平高、因妊娠或药物不良反应停用TKI与停药后焦虑等心理问题的发生显著相关。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yuan MY, Li ZR, Zhang XS, et al. [Incidence and associated factors of tyrosine kinase inhibitor withdrawal syndrome and psychological issues in patients with chronic-phase chronic myeloid leukemia after therapy discontinuation]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41339046. doi:10.3760/cma.j.cn121090-20250328-00155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。